Chris Shibutani
Stock Analyst at Goldman Sachs
(2.50)
# 2,394
Out of 4,979 analysts
96
Total ratings
50%
Success rate
1.35%
Average return
Main Sectors:
Stocks Rated by Chris Shibutani
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PCVX Vaxcyte | Maintains: Buy | $138 → $100 | $32.41 | +208.55% | 2 | Apr 1, 2025 | |
| ERAS Erasca | Maintains: Buy | $3.5 → $3 | $1.56 | +92.93% | 7 | Mar 21, 2025 | |
| MCRB Seres Therapeutics | Maintains: Sell | $20 → $15 | $22.85 | -34.35% | 4 | Mar 14, 2025 | |
| ALKS Alkermes | Maintains: Buy | $30 → $32 | $28.45 | +12.48% | 7 | Feb 14, 2025 | |
| BNTX BioNTech SE | Upgrades: Buy | $90 → $137 | $102.66 | +33.45% | 7 | Nov 8, 2024 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $30 → $33 | $16.33 | +102.08% | 3 | Nov 7, 2024 | |
| UTHR United Therapeutics | Maintains: Neutral | $243 → $302 | $394.62 | -23.47% | 4 | Nov 1, 2024 | |
| RPRX Royalty Pharma | Maintains: Buy | $50 → $51 | $35.80 | +42.46% | 3 | Aug 14, 2024 | |
| JNJ Johnson & Johnson | Maintains: Neutral | $160 → $155 | $178.13 | -12.98% | 3 | Jul 19, 2024 | |
| AMLX Amylyx Pharmaceuticals | Maintains: Neutral | $3 → $4 | $10.44 | -61.69% | 8 | Jul 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $18 → $20 | $10.47 | +91.02% | 5 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $650 → $723 | $738.64 | -2.12% | 6 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $29 → $26 | $19.44 | +33.74% | 1 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $134 → $153 | $143.80 | +6.40% | 2 | Jan 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $173 | $209.79 | -17.54% | 4 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $44.33 | - | 4 | Nov 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $81 → $69 | $46.72 | +47.69% | 5 | Oct 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $13 | $20.46 | -36.46% | 2 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $20 → $23 | $41.06 | -43.98% | 3 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $2.38 | +2,000.84% | 1 | Dec 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $52 | $43.26 | +20.20% | 2 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $47 → $60 | $24.55 | +144.40% | 2 | Dec 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $18 | $5.29 | +240.26% | 4 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $17 | $6.81 | +149.63% | 1 | Sep 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.71 | - | 1 | Jul 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $6.59 | - | 1 | Feb 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $4.56 | - | 4 | Jan 24, 2018 |
Vaxcyte
Apr 1, 2025
Maintains: Buy
Price Target: $138 → $100
Current: $32.41
Upside: +208.55%
Erasca
Mar 21, 2025
Maintains: Buy
Price Target: $3.5 → $3
Current: $1.56
Upside: +92.93%
Seres Therapeutics
Mar 14, 2025
Maintains: Sell
Price Target: $20 → $15
Current: $22.85
Upside: -34.35%
Alkermes
Feb 14, 2025
Maintains: Buy
Price Target: $30 → $32
Current: $28.45
Upside: +12.48%
BioNTech SE
Nov 8, 2024
Upgrades: Buy
Price Target: $90 → $137
Current: $102.66
Upside: +33.45%
Syndax Pharmaceuticals
Nov 7, 2024
Maintains: Buy
Price Target: $30 → $33
Current: $16.33
Upside: +102.08%
United Therapeutics
Nov 1, 2024
Maintains: Neutral
Price Target: $243 → $302
Current: $394.62
Upside: -23.47%
Royalty Pharma
Aug 14, 2024
Maintains: Buy
Price Target: $50 → $51
Current: $35.80
Upside: +42.46%
Johnson & Johnson
Jul 19, 2024
Maintains: Neutral
Price Target: $160 → $155
Current: $178.13
Upside: -12.98%
Amylyx Pharmaceuticals
Jul 12, 2024
Maintains: Neutral
Price Target: $3 → $4
Current: $10.44
Upside: -61.69%
May 6, 2024
Maintains: Neutral
Price Target: $18 → $20
Current: $10.47
Upside: +91.02%
Apr 11, 2024
Maintains: Neutral
Price Target: $650 → $723
Current: $738.64
Upside: -2.12%
Mar 1, 2024
Maintains: Neutral
Price Target: $29 → $26
Current: $19.44
Upside: +33.74%
Jan 25, 2024
Maintains: Buy
Price Target: $134 → $153
Current: $143.80
Upside: +6.40%
Dec 11, 2023
Upgrades: Buy
Price Target: $173
Current: $209.79
Upside: -17.54%
Nov 9, 2023
Upgrades: Outperform
Price Target: n/a
Current: $44.33
Upside: -
Oct 30, 2023
Maintains: Buy
Price Target: $81 → $69
Current: $46.72
Upside: +47.69%
Mar 3, 2023
Maintains: Neutral
Price Target: $15 → $13
Current: $20.46
Upside: -36.46%
Mar 1, 2023
Maintains: Neutral
Price Target: $20 → $23
Current: $41.06
Upside: -43.98%
Dec 19, 2022
Initiates: Buy
Price Target: $50
Current: $2.38
Upside: +2,000.84%
Dec 16, 2022
Maintains: Buy
Price Target: $40 → $52
Current: $43.26
Upside: +20.20%
Dec 13, 2022
Upgrades: Buy
Price Target: $47 → $60
Current: $24.55
Upside: +144.40%
Nov 8, 2022
Maintains: Neutral
Price Target: $13 → $18
Current: $5.29
Upside: +240.26%
Sep 7, 2021
Initiates: Buy
Price Target: $17
Current: $6.81
Upside: +149.63%
Jul 14, 2020
Initiates: Outperform
Price Target: n/a
Current: $1.71
Upside: -
Feb 10, 2020
Initiates: Outperform
Price Target: n/a
Current: $6.59
Upside: -
Jan 24, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $4.56
Upside: -